Physician profile
Cesar Deleon
NPI 1134282411
$4,849.31
in general payments reported to CMS, 2019-2025
22 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $520 · 2021: $1,003 · 2022: $352 · 2023: $393 · 2024: $818 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,220.84 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $858.58 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $467.21 | 2019-2025 | Repatha, Otezla, Tepezza |
| Almatica Pharma LLC | $266.58 | 2022-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Edwards Lifesciences Corporation | $244.78 | 2025 | |
| Amarin Pharma, INC. | $219.97 | 2019-2022 | |
| Lilly USA, LLC | $216.67 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $176.48 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $161.04 | 2021 | |
| Esperion Therapeutics, INC. | $129.16 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $123.71 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $116.04 | 2021 | |
| Astellas Pharma US INC | $115.27 | 2019 | |
| Abbvie INC. | $104.43 | 2023 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.92 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.68 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $81.82 | 2019-2020 | |
| Arthrex, INC. | $45.00 | 2019 | |
| Sanofi Pasteur INC. | $43.20 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $39.02 | 2019-2020 | |
| Glaxosmithkline, LLC. | $14.55 | 2025 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.